ZIOP - Earnings call transcript Q3 2019 | Alaunos Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen. Thank you for standing by and welcome to the Ziopharm Oncology Third Quarter 2019 Results Call. At this time all participants are in a listen only mode. Later we will conduct the question-and-answer session and instructions will follow at that time. [Operator instructions] As a reminder, this call may be recorded.

to conference like to now would turn over the Mr. I Relations Vice Communications. President Taylor, and of Chris Investor Corporate Sir, please go ahead.

Chris Taylor

the to Thank the our you, Oncology results This webcast Ziopharm quarter filed our in our release, to welcome of XX-Q ziopharm.com. for afternoon, website, review and we operator. Good available conference both of afternoon, call of Investor's and are third section XXXX. quarter third issued the news and which

a have also also Section. PowerPoint included our For set informational webcast commentary. can of to our slides website purposes, be today's accompany we Investor's slides in on in These the found

information, During this business statements, therapeutic forward-looking the trends. call, of potential company financial the candidates in a pipeline, and number statements development regarding make including our will risks, regulatory

risks time. as with to in that Forward-looking described XX-Q other to subject make we and may statements time are and from uncertainties within filings SEC numerous the our

call Executive Dr. today be for will David Participating Satyavrat CFO. and Dr. on President, Officer, our Shukla, Ziopharm Chief Cooper, Laurence Mauney,

from free queue. management and time, for of will In we that Q&A. to our return please team, open interest call kindly then feel have and the one the follow-up request you question to the we commentary Following

Thank over Good turn afternoon, to things David. the you. And to off, I'll lead call David Mauney.

Dr. David Mauney

individualized in the late with tumor program, Thanks, blocks to we TCR have building everyone. afternoon of with our large cancer have effort Ziopharm Since towards therapies. the to market solid big believe Chris we our vision. XXXX, and good a progressively and is where address a patients very technology company focus we shifted an

It has we transfer allow is peer agnostic non-viral type. can platform we rival the be to that are TCR-T, target can with cancer widely It there to published. going subspecialties. into Dr. patient world for experience years we manufacture with tumor us scientist And in ever for used week, as with When a center the have considered stop have with confirmed clinician gene We which to and broad NCI, last a that already been largest in us. interest drugs the oncology clinical who just of and clinic or clinically partnered time we didn't totality, specific Rosenberg. of believe a starts the unaware technology platform the any that validated, the world-leading Steve solution across in the our first at be multiple

patients, now enjoy and the samples, MD full We access Anderson will to institutionally. punch of

success-based in demonstrating are in the the going institution future, forward. confidence deal the paid and of the economics full places The our program

and believe Ziopharm. scientist Additionally, help lead we of world-class recruited TCR-T of from have within our licensed for key the what relevant library walls the TCRs NCI have a path we to is clinical a

be in team companies our to from proud out for building rapidly are highly We and Novartis, Ziopharm. like join successful industry Houston recruiting and experienced to are away leaders example,

Finally, II is the TCR-T patients our about Phase in to in a using the first trial. treat technology NCI

as and compared pleased terms for lymphocytes the and saying best clinical TCRs to the savings moving goes are will and fighting the cells As go believe or in peripheral Laurence significant infiltrating that past money. many to with tumor are example. drug Phase modified as will TIL, II, choice Phase field, we on own based a history, healthy T patient's I that of we in genetically blood cancer that warriors beyond it straight are time without Along in result others detail, to of

not as and to have commercialization program opportunity exclusively. the the and and under agreement multiple modifying by the belief abundantly full cells the one it non-viral Beauty took our payable more is recently will to CRADA performed the Ziopharm's experience a that this its the TCR fact, continuum Rosenberg's that eye manufacturing of to importantly, peripheral to ownership in single-digit T under controls briefly TCRs. to to In partners. evolved we TILs commercial using to compared milestone to its see. number our restate being economics, from has express Dr. With intellectual the and shows make Ziopharm but of Sleeping work an robust, rights property a clear that We genetically minus about approach. X-K following market holds we a proactively program, To own large NCI to rights cheaper with ownership relationship now blood for be CRADA, always all TCR and facts, clinical fees, IP commercialization with viral rights, payments, reminded approach royalties a scalable, towards practical, regards an It

develop way, Beauty certain In Sleeping Beauty. CRADA, rights cannot NCI Or Sleeping In specifically purpose in the agreement, the solely Ziopharm to XXXX develop oncology licensed XXXX, for that May in for The products retains to The TCRs property commercialize the seeking conducting products, all related gene but already express NCI another rights families to exclusively the fields, has IP TCRs Beauty to Sleeping under transposon-mediated blood CRADA. families research adding commercialize NCI the TPXX said to mutated transfer, license KRAS, products. use Ziopharm utilize. to of we same of reactive to peripheral EGFR hot actively something the agreement by license, from and autologous are engineered additional hotspot intellectual the also and the spots. this therapy T contemplates cell

of discussed be haven't outside recently, the to activities we company While robust. continue our it

We most ongoing that potential will with have partners the value. and believe we conversations clinical data significant drive

investors engage to new to continues initiatives with up. ramp Our potential

for broader spread. investment expanded risk what think is push biotech speaking investors we to sophisticated base a opportunity a are share of an of continue terms significant around a base and with in We reward

such presenting London. exposure reminder, a be this Jefferies Morgan We banking will are adding additional later And as month Stanley. through conferences, we investment at as in

embrace that a in space, promising our and recognize company products As significant growth oncology will the enters highly commercializing we period of progress. parties all a developing towards not

likely only to desire we It detractors. to that prove In rest often them highlighting is continue wrong. detractors our will these most vocal are reinforce have assured, fact, misinformed, and worth they

course, the and which working on not. milestones, execution Of we aggressively do control data, those proper clinical elixir those to for we are and where assistance all we deliver provide is on best

to and We into XX proud company year, have a as summarize, data remain our on that To over ahead. executed charter to steadfast clinical months forward we the an look the last independent lies TCR and untapped focused core more solid efforts licensed tumors. for expand the IP IP. continue largest around develop and and critical markets plan the license to will assets exclusively further and in We prioritize

in our bioinformatics, and in efforts screening, refine We continue to manufacturing. technology, including

a we skills a from this an base the to support help run trials signed We critical with milestones and and aligned building the and library. and build in cancer assure team us that the the world, a vision. smart board are agreement investor with clinical to pass We very center supportive to capital raised largest

trial. His opportunities now, to many immunotherapy a just playing you, could of impact ago patients, cancer tremendous. and await out And provide the all are not rational, predictions but first on was Phase of scalable, now an like Laurence's we ahead some groundbreaking the cost-effective vision are patient a years that lie them. markets II in that real-time have

to call the turn Laurence. over I that, With

Dr. Laurence Cooper

everyone. afternoon good and David Thanks,

call. have As which since is progress, for our made cornerstone last Ziopharm's to even future mentioned, our program significant TCR-T solid one we tumors, for

at NCI. start clinical Let you our by me updating the work on

Rosenberg this that trial Dr. infusion modified system the targeting As of express Sleeping trial under control genetically a team. more personal TCRs one The are with of reminder, the Beauty is evaluates and T to the or cells neoantigens. his

trial, We is the which since are the II call. our a NCI with Phase change positive pleased that for a last quarterly IND is

highlight, in at clinic the we NCI endpoint patients in associated will will variety every how The participants a Recall cells with a deal data patient and will seen enrolled cancers. the is each now To reveal a rate. the response solid Dr. following will of T months and that cells few tumors, infusions. likely being months, which weeks of T patients primary closely with and tackle be learn enrolling great Rosenberg be followed range available every from the tumor Thus,

We tumor succumbs T will to infusions. type learn the how each cell

target of the trafficking We tumor, will which to how includes sites these T cells learn cancer. persistence and

you these the X.X solid with the can patients, Ziopharm can solution XX% Dr. that massive approximately Dr. of patients of The represent of which tumors XX% on NCI. Rosenberg T us. United new tumors. CRADA million in estimates cases for to each in with States. opportunity our a I with cells provide for are year based opportunity we so, There of want target sense or most, developing the Rosenberg a are over recognize with cancer antigens

Dr. Furthermore, to clinical that express specific Beauty cells and given Sleeping Rosenberg's significant upon and system be administration genetically demonstrated of selected this has clinical can experience Beauty modify specific The the trial used CDXX T CAR. TCRs. grade the was responses seen to team Sleeping system neoantigen published for human

We in step dialogue and patients close first you, enrollment The and then with Dr. like next await number is of Rosenberg dose. a the to indications. patient broader are opening

the does significant not creation. number timing on result data, that Ziopharm and of While we in control can the NCI's know information of even value patients release small do a

why points are There we important are that support assertation. X It's to note of confident data important work. this technology so will clinical in this

melanoma. of lymphocytes, based we on or in is T infiltrating that know patients primarily cells with can TILs, solid is first target some The tumors. infusion This the tumor

the recognize The successfully neoantigens. second via or that T cancers' their that understanding TILs so is receptors, do tumors, targeting TCRs cell

than their scientific derived not therapy that TILs, the young and leading can into is that tumors to create other struggle genetically and experiences solid that modified, specific Ziopharm the of melanoma. to recycle genetic tumors. for engineering is blood peripheral out built using the following clinical run cells are And TCR-T fourth upon killing. can a X TCRs these target third insert gas last from T advances which neoantigen therefore the The typically

of cells Firstly, approach Sleeping non-viral to System. the based we low-cost, scalable, on developed Beauty genetic engineering T a

genetically to of we the to to And and the commercialization. exhausted harnessed the system Sleeping needs this cells from modify from used scale system's which third, we of cells overcomes Second, blood, patients ability demands tired TIL. or peripheral T Beauty infusing meet T

property example, an T our NCI, spots. For will targeting intellectual manufacturer, our partnership trial, cell therapy, clinical targeting open at key surrounding with in cell II to relationship the the trials. to This TCRs the to beginning personalized exclusivity execute T or IND own a whether now, MD ide cells, Anderson T and multiple work, hot resulted for for needed, targets, operate, has TCR with TCRs be infusion and on of individual Phase

on announced to our strengthen me next engagement the Anderson, R&D program, TCR-T agreement brings is making months our MD are was update Anderson. with which delighted the in to This the we This recently wanting and is multiple with work The oncology from secured and things reciprocal X us. investigators with The MD Ziopharm. buy-in to following already the them. for excitement as within accomplishes subspecialties leading agreement we've

we at we the patients world more to partnering access we are other single largest with center center. any cancer the now Firstly, enjoy than and could in

Secondly, words, biology. In trials for important cancer TCRs genes solid EGFR. it accelerates initial and tumors. lastly, clinical implement library of of expansion the TPXX, allows that families us hotspots of it Ziopharm-led in drive X really And the other KRAS, and to

provides TCRs and patients regarding are We molecules. from will already additional words, mutations three respect a broaden current application. to diversity MD points NCI believe library, the enable HLA Anderson, design. increasing a I covers In with initial of enroll multiple library advantage. maps There will library existing TCR the competitive and at the This the would library us to the to like library from further make trial other the us to

T reduce Firstly, to time will which hotspot the cells us screen deliver TCR for weeks. simply targeting library the cancer to to patients mutations, allows

be the had enough number the a success. Anderson. at that already TCRs greater likelihood can clinical lastly, patients larger library the the and begin we of greater of the Secondly, to And trial library, our in MD the treated

MD In led of growth accelerating pace new for X addition Ziopharm provides this clinical agreement to the the library, trials. new TCR Anderson at with a foundation

test. from TCRs hotspots are targeting is inpatients first utilizing the with that screened a simple a rapidly trial blood The library,

mutation patient we execute today, the NCI then in manufacture the personalized if have is does individual for trial much like product a not second a protocol The a a hotspot, neoantigens. to on will

and look more progress We the on of year. great are these trials next providing color to timing early forward making

TCR-T, American TCR-T, present or pleased aligned on in bound IL-XX the generation which control have tumors, the of development, next success at Sleeping in using centers with preclinical of be system. to leading achieve be rapid to the TCR are run membrane trials. the regard path the of data in and our Beauty Hematology the personalized cure To we based playbook, we our to on a and December must groundbreaking cancer solid With to co-expression this Society of manufacture, is RPM, technologies

have this over We achieved past three all year.

call update. two a on to before other over Finally, for our summary the Satyavrat turn programs I a financial

to with rapid personalized is day is that gene dose as the therapy T-cell The soon models. after target XX% also Turning CDXX This program. under the preclinical that the the membrane-bound based our RPM, CAR-T. viability second Sleeping control of program, on goal and of of greater, as prove to can as our demonstrate the And to cells specific platform. cells Beauty we in tumor, transfer, build grow manufacture, the CAR-T on IL-XX program it's they or did or

to data path technology approved the Since think in we the most rights the path. important to CAR we date, fastest the is only the have human to

we therapeutic all result, We to a this the I cleared for Xst and obtained them, uncovered in October wrote had available an opportunity an have announced trial. patients year. IND that options the who Phase FDA limited clearance a IND, on As clinical

allogeneic We marrow will of Ziopharm MD infusion be work transplantation. leukemias remains will donor-derived This to RPM relapsed who autologous the conducted after with CDXX. bone program our Anderson. CDXX committed in RPM and at targeting expressing for patients CAR-T lymphomas have study evaluate

and planning greater establishing In a undertaking steady has sites submissions. addition, an of trial progress China clinical actively on in facilitate is to regulatory hospital steps Eden BioCell autologous and network made

We were Phase in the Science controlled our monotherapy pleased trial Medicine. program. link report the to from In that are data be Turning published A can I August, Translational to IL-XX we to enrolled publication supported monitor in website. Libtayo, benefited to study. our and our monotherapy to on progress the enrollment those had the found studies both with we from in Opdivo expansion combination continue patients and

in additional trial the XX now Opdivo have been The patients enrolled.

end study Libtayo the patients the patients the enrolled we X monitoring and enrollment. period in first been required are resume those of The have nearing before

for month. We are of Society preparing our this the Neuro-oncology later presentations X poster

As we study the combination with for year, data did to and both study plan interim at we present I ASCO the monotherapy earlier Opdivo. this Phase

now, we'll Satyavrat financial to And with hear QX. Shukla, our commentary a from CFO, related

Satyavrat Shukla

create excited to It's for very bring Thank and to disruptive great paced I technologies a at am three you, as fast Ziopharm executing the our milestones, the advance intensely immunotherapies our Throughout the market. investors. organization, on community efforts me and value a advance our Laurence. to our for for strategic company for initial on months is patients build team focused to we transformative achieve been plan and which our will

specific the XXXX. for quarter results to turning financial Now, Ziopharm's third of

news of expenses of million our the million in quarter XX-Q, XXXX and of and $X.X $X.X quarter noted million year. of research As to the G&A for were QX compared for for last XXXX, third third to $X.X release $X.X expenses XXXX. million were development compared QX for

to of On $XX.X loss shareholders loss the applicable $XX.X recorded exercise with a of to net the of million, or Reflecting the was we $X.XX for $X.XX cumulative that one-time, from of or compared XXXX non-cash a non-cash the quarter warrant basis, a for financing per charge completed in QX. common $XX million we share charge, net the per third share, XXXX. million third quarter associated

second purposes reported For we first quarters and or exclude if had share, $XX.X loss million, year. charge in million, one-time, the informational this with of non-cash line net been the net in $XX.X the loss, $X.XX only, per which of

in cash ended we our $XX On investors, by resources the announced quarter with agreement million. than existing financing company. Partners, past entered into providing of more the that during $XX The MSC led warrants, the unrestricted approximately exercise of this to quarter, proceeds side, a to company an million group

$XX.X preclinical by to balance prepayment Center. of work approximately MD Additionally, conducted company we be also a for and clinical the Anderson million Cancer at have

into three the see capital our and we prepaid our in To summarize, takes cash to We our sheet our Anderson, half into core have the readouts we we XXXX. our in million to significantly liquidity programs. MD -- third each critical strengthened $XXX financial more the quarter. balance sufficient data sheet of have with work fund business of put Combined us to at believe capital than first of

And now, Laurence call a thought. will I final the back to for hand

Dr. Laurence Cooper

past of putting pieces Thank accomplished the mission company. to in proud we We're in In year. closing, to become indeed to today all key the you. our global are quarter, immune-oncology been has past attain and leading a stage enable that place Ziopharm commercial

With that, to questions. we'll return the the call operator for

Operator

Raymond Instructions] James. [Operator question Your of Novak from comes David first

now is line Your open.

David Novak

might completing expanding the agreement to be at to Anderson a the how thoughts to the how Anderson be I will program, specifically new So will was the complement maybe IND-enabling provide or the expand us off, you hoping bit to it done MD versus work you how being library R&D at will from prioritizing color the as it of with able studies. around development? And TCR MD NCI differentiated some NCI, TCR work be kick

Dr. Laurence Cooper

the versus this The would studies, there's to to So in parts therapy IND-enabling the terms completing part therapy. is cell that they go actually identifying think the One about I investors is of way the T like of the basically two prioritization receptors. hand-in-hand.

instance, For hotpot against T receptors cell mutations. the

the T engineering And cells genetic receptors. the to the express of those is part cell T second

IND the part second the you if the of for the the You'll actually for manufacture, puzzle, recall NCI would. that playbook is that at

been that So T-cell cassette-based different allow -- swap plasmas a when talk to targets done. that mentality playbook We essentially target. T-cells generate we you about us essentially into particular generate in to for have studies, essentially IND-enabling receptors those and use have each the

with really is R&D agreement. built now tight generation that studies we that IND the have MD we property will, have solid them of robust importantly, tumors. with those the under foundation. really with members the us receptors, access institution T-cell the of many, And It who cell to the on if many of faculty have have work, prioritization receptors. relationships of there, T actually really the discovery allows with key Anderson, relationship associated the really leaders this intellectual The have at patients So to you the

can our personalized And we in into synergy biologic then, handle us receptors T the as our a library essentially to footprint on add this essentially into investigators laboratories. and samples that these actually hotspots. to Anderson MD we to mentioned for going our And between flow cell release, material. the therefore allows, that That to either are or expanding look the basis, the would are tissue we in press use

a a is think we for this about, So manufacture. I the way playbook Because essentially as win. have

We have to the the whole able after the the whatnot TCRs would, using by you to go using playbook, the the thing the receptors. or generate technology And materials essentially we're be Anderson jumpstarted cells. MD has from the SOPs been we're T and NCI because if to manufacturing essentially T discover to their cell and

David Novak

going a ASH viability of XX% of grafting in I follow-up, your RPM bound the and And yesterday, not should that prepared cells remarks. I've abstracts at IL-XX, TCRs, across at viability company around through XX% you both CARs different clinically number as as viability. questions two in believes RPM highlighted quick a grafting from in why received interesting be detailing and ones membrane came materially cells co-expressing

And comments some also, to membrane maybe significance around of the that. drive both in some tackle vivo IL-XX heterogeneity? and around persistence bound comments So

Dr. Laurence Cooper

of terms viability. in the So

basis that's actually preclinical to really the IND. much product highlight, to in doesn't just, question. the is by that looked viability. And be Whether just our the we've greater the that And a threshold They kind has Ziopharm at of again, really are difference drug. models. outcome make and terms guided in living XX% has say or this the is there of benchmark the of So cells XX% agency. XX% achieved or

those that with T that to again, cells cycle, grow go essentially allows putting you're are those into cells doubling patient. TCR viable, that T have the for grow a say statements will and the and so able that begat, to cells CAR so double now, cells, into the if patient. cell, and forth is more IL-XX will So reason the in cells, bound we modified The XX% and in cell, in T body, that they that we're confidence on, in these accelerator, when membrane modified baked the our then

at mind different get heterogeneity the triggers -- to So slightly in thought. that actually that's a my question,

So to crux here, I the your want get sure I of make question David.

worked bloodstream, once pool. potential really when naive shorten hard and to generating cells, of capture for we the it's to us, the that we're the the put especially T that of deliberately into membrane-bound cells has think instance, the So pool we've using that IL-XX, out come for very Because back cells the greatest patient. manufacturing heterogeneity of

with we the essentially of differentiated. can after So cells growth keep, be all the that our infusion. technology survive the restricted so if incubator, the companies call a flavors of of be them unlike the other cells patient essentially to portfolio, actually cells that to their person's And return back and can actually thereafter. heterogeneity, those would, closed come you be as ability their being their we terminally out soon bloodstream go in on Whereas through in we the T can rapid, door the full what

Operator

Capital. next with from Thomas Your comes Street Lake question Flaten

Your line now is open.

Thomas Flaten

question talk commitments -- should the expecting in be additional to already think how then across to required as commitment Can you that you're as that programs CAR-T going the we and well advance the post-XXXX. the against or Anderson, XXXX? that's Specific the a of exists make MD TCR pre-funding distribute bit about and about a around how prepayment to little

Dr. Laurence Cooper

which Those -- that money actually program available. CAR in and MD So increasingly, JSC, committee are member. of makes is Anderson Joint programs we a also essentially the program. the Committee, And a well the and as member Ziopharm reviews call and TCR as steering is Ziopharm the spend invested then we Anderson resources what MD the is relationship how about by the Steering governed

play going clinical the space. for around running the put you're So building trials what that and I've and importantly, time, X described for and out TCR-T infrastructure over see into completing to is available our funds

Thomas Flaten

of have for or sense you program? could with then timing CAR-T the of provide MD any us do initiation some you Anderson the And --

Dr. Laurence Cooper

Yes, the hard of open the to that year. end really so working we're trial by

Operator

question comes Sean H.C. Lee next from of Your Wainwright.

line open. is Your now

Sean Lee

Just U.S., a donor-derived venture joint do while an to a in CAR-T that doing one Eden on program. with noticed you autologous study in BioCell. are the quick I planning the study

what's So these behind both wondering not programs? other rationale or for I on two parallel the was one Why studies? focus the

Dr. Laurence Cooper

a really issue. it's So sequencing

So we fastest manufacture with sense saw really and in China. rapid T path as patients cells. and RPM both start alike. technology allogeneic the personalized greater committed or the autologous of clinic we States investors to the of the a That CAR-T We're the to to still for the really and the get United in

I more purposes as And in say people, for the have So our community that we've rolling. through money, essentially investor that's essentially now it it way greater it work up. essentially we'll and about trials has in the relationship momentum, to China think funded is the has the And it's BioCell. would then Eden of bubble the has

MD terms In the money that's CAR-T programs. the to essentially the also, could agreement and of States, used at it's Anderson if really, the would, prefunded. you run MD that's United the Anderson be Because somewhat that work in

Operator

have remarks. the time, Cooper I Thank back we final no you. call further will At to and questions this Dr. turn for

Dr. Laurence Cooper

good a and thank you. everyone I Thanksgiving and come to everybody very week wish Thanks much

Operator

and today's much call. conference you Thank concludes Ladies this for gentlemen, so participating.

You disconnect. may now

Alaunos Therapeutics (TCRT) 10 Nov 192019 Q3 Earnings call transcript